This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Hang on a second…

This CME Activity has expired and is no longer available for credit.

A Changing Paradigm: Addressing Unmet Needs in Hemophilia A

A Changing Paradigm: Addressing Unmet Needs in Hemophilia A


Clinical Review

Time to Complete

30 minutes


September 26, 2018


September 25, 2019
Add to Queue

Maximum Credits

0.50 / AMA PRA Category 1 Credit(s)TM

Accredited Providers

This activity is jointly provided by Postgraduate Institute for Medicine and RMEI Medical Education, LLC.

Commercial Supporter

This activity is supported by an independent educational grant from Genentech.

Program Description

An estimated 60% of patients with hemophilia A have the severe form of the disease, which often leads to recurrent bleeding episodes into the joints.1 Recurring joint bleeds can result in debilitating joint disease and chronic pain, which negatively impacts the quality of life of patients living with hemophilia and contributes to significant disability. Patients who have hemophilia A with inhibitors represent an area of unmet need, since they suffer from worse outcomes because their disease is more resistant to prophylaxis and treatments. Hematology providers are challenged to manage hemophilia A and are even more challenged to manage hemophilia A with inhibitors. They also need to remain current with new developments in the field that could dramatically improve patients’ outcomes. While adherence, outcomes, and satisfaction are improved in patients who are engaged and participate in their healthcare decisions, hematology providers may not actively engage in shared decision making with their patients.

Intended Audience

US-based clinicians, including hematology and hematology/oncology and hematology/oncology nurse practitioners and PAs.

Educational Objectives

After completing the activity, the participant should be better able to:

  • Differentiate efficacy and safety data between current, novel, and future therapies for treating patients with hemophilia A without inhibitors and integrate their use into practice
  • Incorporate appropriate management of hemophilia A with inhibitors in the treatment paradigm, based on the efficacy and safety, and mechanisms of current, novel, and emerging therapies
  • Describe the mechanisms of action of emerging and novel targets beyond factor VIII and how these may be integrated into the treatment of hemophilia, based on the pathophysiologic underpinnings of the disease
  • Employ a strong patient-provider collaborative approach to managing patients with hemophilia A that includes recognition and management of quality of life issues in patients with hemophilia A, and incorporates shared decision making

Conflict Of Interest Disclosure Policies

The Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.


Steven W. Pipe, MD
Professor, Pediatrics and Pathology
Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases
Pediatric Medical Director, Hemophilia and Coagulation Disorders Program
Director, Special Coagulation Laboratory
University of Michigan
Ann Arbor, MI

Dr. Pipe has affiliations with Alnylam, Bayer, Biomarin, Bioverativ, Catalyst Biosciences, CSL Behring, DNArx, HEMA Biologics, Novo Nordisk, Pfizer, Roche/Genentech, Shire, Spark Therapeutics, and uniQure (Consulting Fees); Shire and Siemens (Contracted Research).

Accredited Provider Disclosures

The PIM planners and managers have nothing to disclose. RMEI Medical Education, LLC planners and managers have nothing to disclose.




AMA PRA Category 1 Credit(s)TM

Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and RMEI Medical Education, LLC. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.




By reviewing the course and successfully completing the content and evaluation, physicians, nurse practitioners, and PAs are entitled to receive up to 0.50 AMA PRA Category 1 Credit(s)TM . A statement of credit will be available to print immediately. Users must:

  • Read the learning objectives and faculty disclosures.
  • Participate in the activity.
  • Complete the activity evaluation.

Physicians, nurse practitioners, and PAs who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you would like to contact Postgraduate Institute for Medicine, please email


Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue